ARQT
Arcutis Biotherapeutics, Inc. · Healthcare
23.27
1.63%(-0.39)
Close24.05
3.35%(+0.78)
After HoursLast Updated: — ET
52W L: $11.8652W H: $31.77
$23.29
CHG-0.66 (-2.76%)
H$25.53
L$21.00
VOL21M
ARQT (1h)
Arcutis Biotherapeutics, Inc. · Healthcare
Mr. Taylor brings a strong track record launching multiple high-profile therapies, most recently serving as Senior Vice President, Sales at Arcutis Biotherapeutics (Nasdaq: ARQT), where he led U.S. sales efforts for ZORYVE®, a next-generation topical PDE4 inhibitor; previously, he held leadership roles at Incyte (Nasdaq: INCY) supporting the launch of OPZELURA®
Phocas Financial Corp. cut its position in Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) by 39.3% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 64,499 shares of the company's stock after selling 41,808 shares during the period. Phocas Financial
Arcutis today announced that Arcutis management will present at the 25th Annual Needham Virtual Healthcare Conference, taking place April 13-16, 2026.
Investigational ZORYVE® (roflumilast) cream 0.05% was well tolerated with safety findings consistent with prior pediatric experience in the INTEGUMENT program ZORYVE cream improved signs and symptoms of mild to moderate atopic dermatitis in infants aged 3 months to less than 24 months over four weeks Caregivers reported rapid improvement in itch in as little as 10 minutes in nearly half of infants Results from additional studies across the ZORYVE portfolio being presented in three poster presentations WESTLAKE VILLAGE, Calif. and DENVER, March 28, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced new data from the INTEGUMENT-INFANT Phase 2 trial demonstrating that ZORYVE® (roflumilast) cream 0.05% reduced signs and symptoms of atopic dermatitis, the most common form of eczema, in infants aged 3 months to less than 24 months with mild to moderate atopic dermatitis.
WESTLAKE VILLAGE, Calif., and DENVER, March 18, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will present new data from its clinical development program and marketed ZORYVE® (roflumilast) portfolio during the 2026 American Academy of Dermatology (AAD) Annual Meeting taking place March 27-31 in Denver.
Ally Bridge Group NY LLC bought a new position in shares of Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) in the undefined quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 233,220 shares of the company's stock, valued at approximately $4,396,000. Arcutis Biotherapeutics accounts for approximately 2.7%
Welgus Howard G.
director
10,000 SH @ $23.88
2026-04-01
Leonard Keith R
director
12,220 SH @ $7.51
2026-03-02
Leonard Keith R
director
27,052 SH @ $8.63
2026-03-02
Leonard Keith R
director
39,272 SH @ $25.39
2026-03-02
Leonard Keith R
director
12,220 SH @ $7.51
2026-03-02
Leonard Keith R
director
27,052 SH @ $8.63
2026-03-02
Welgus Howard G.
director
10,000 SH @ $25.65
2026-03-02
Edwards Larry Todd
officer: See Remarks
30,000 SH @ $0.00
2026-02-27